Detection of human cytomegalovirus (HCMV) pp67-mRNA and pp65 antigenemia in relation to development of clinical HCMV disease in renal transplant recipients

Clinical Microbiology and Infection

Volumn 7, Issue 5, 2001, Pages 254-260

  Degre M ^a   Kristiansen, K I ^a   Rollag, H ^a   Holter, E ^a   Nordal, K P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Detection system; HCMV disease; HCMV pp65 antigenemia; HCMV pp67 mRNA; Renal transplant recipients

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIGEN; VIRUS MESSENGER RNA;

ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BIOASSAY; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG RESPONSE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; LEUKOCYTE; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECIPIENT; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; VIRUS DETECTION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0035352184     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1198-743X.2001.00251.x     Document Type: Article

References (42)

1. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients
2. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients
3. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with PKT3
4. A prospective study of the natural course of cytomegalovirus (CMV) infection and disease in renal allograft recipients
5. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation - A report of 130 consecutive patients
6. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes
7. Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients
8. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins
9. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia
10. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp.65) for optimal quantitation of human cytomegalovirus antigenemia
11. Cyromegalovirus antigen detection in peripheral blood leukocytes after allogeneic bone marrow transplantation
12. Evaluation of CMV antigenemia assay for rapid detection of cytomegalovirus in mixed-leukocyte blood fractions
13. Direct detection of cytomegalovirus in peripheral blood leukocytes - A review of the antigenemia assay and polymerase chain reaction
14. Monitoring for cytomegalovirus after organ transplantation: A clinical perspective
15. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients
16. Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients
17. High level sensitivity of quantitative pp.65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up
18. CMV antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients
19. pp65 antigenemia as a marker of future CMV disease and mortality in HIV-infected patients
20. Prospective study of cytomegalovirus antigenemia in allograft recipients
21. Factors influencing detection of quantitative cytomegalovirus antigenemia
22. Effect of delayed specimen processing on antigenemia test results
23. Usefulness of DNA viral load quantitation for cytomegalovirus disease monitoring in renal and pancreas/renal transplant patients
24. Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: The role of semiquantitative polymerase chain reaction (PCR)
25. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients
26. Quantitation of human cytomegalovirus DNA in bone marrow transplant patients
27. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
28. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: Correlation with disease
29. Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus infected subjects with and without CMV-disease by using PCR and the SHARP signal detection system
30. Surveillance of cytomegalovirus after solid-organ transplantation: Comparison of pp.65 antigenemia assay with a quantitative DNA hybridization assay
31. Diagnosis of cytomegalovirus infection in kidney transplant recipients by a quantitative RNA-DNA hybrid capture assay for cytomegalovirus DNA in leukocytes
32. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients
33. Evaluation of the AmpliSensor PCR and the SHARP signal detection system for the early prediction of symptomatic CMV infection in solid transplant recipients
34. Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation
35. Diagnostic value of monitoring human cytomegalovirus late pp.67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification
36. Evaluation of a new method for early detection of active cytomegalovirus infections. A study in kidney transplant recipients
37. Clinical significance of expression of human cytomegalovirus pp.67 late transcript in heart, lung and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification
38. Human cytomegalovirus suppression of and latency in early pluripotent haematopoietic stem cells
39. Rapid and simple method for purification of nucleic acids
40. Rapid detection of cytomegalovirus infection in immunocompromised patients by different methods
41. Monitoring of human cytomegalovirus infections in pediatric bone marrow transplant recipients by nucleic acid sequence-based amplification
42. Human cytomegalovirus immediate-early detection by nucleic acid sequence-based amplification as a new parameter for pre-emptive therapy in bone marrow transplant recipients